Dopamine D2 receptor knockout mice develop features of Parkinson disease

Annals of Neurology

Volumn 66, Issue 4, 2009, Pages 472-484

  Tinsley, Rogan B ^a   Bye, Chris R ^a   Parish, Clare L ^a   Tziotis Vais, Angela ^a   George, Sonia ^a   Culvenor, Janetta G ^a   Li, Qiao Xin ^a   Masters, Colin L ^b   Finkelstein, David I ^a   Horne, Malcolm K ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BETA ACTIN; DOPAMINE; DOPAMINE 2 RECEPTOR; RAB PROTEIN; UBIQUITIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL INCLUSION; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM STRESS; GENE DELETION; GENE EXPRESSION; IMMUNOREACTIVITY; KNOCKOUT MOUSE; LEWY BODY; MOUSE; NERVE CELL NECROSIS; NERVE FIBER DEGENERATION; NERVE SPROUTING; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; SUBSTANTIA NIGRA; WILD TYPE; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; SUBSTANTIA NIGRA;

EID: 70449368925     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21716     Document Type: Article

References (79)

1. Alam ZI, Daniel SE, Lees AJ, et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997;69:1326-1329.
2. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196-1203. (Pubitemid 27364841)
3. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389. (Pubitemid 19037600)
4. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 1998;13(suppl 1):24-34. (Pubitemid 28221476)
5. Zigmond M, Hastings T, Perez R. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat Disord 2002;8:389.
6. Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 2000;7:240-250.
7. Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978;14:644-653.
8. Ben-Shachar D, Zuk R, Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 1995;64: 718-723.
9. Norris EH, Giasson BI, Hodara R et al. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem 2005;280:21212-21219. (Pubitemid 40805683)
10. Arima K, Ueda K, Sunohara N, et al. Immunoelectronmicroscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res 1998;808: 93-100. (Pubitemid 29003204)
11. Baba M, Nakajo S, Tu PH, et al. Aggregation of alphasynuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998;152:879-884. (Pubitemid 28173348)
12. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-989.
13. Irizarry MC, Growdon W, Gomez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998;57: 334-337. (Pubitemid 28182631)
14. Spillantini MG, Crowther RA, Jakes R, et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998;95:6469-6473. (Pubitemid 28249037)
15. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
16. Eliezer D, Kutluay E, Bussell R Jr, Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol. 2001;307:1061-1073. (Pubitemid 33029953)
17. Uversky VN, Gillespie JR, Fink AL. Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins 2000;41:415-427.
18. Krishnan S, Chi EY, Wood SJ, et al. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis. Biochemistry 2003;42:829-837. (Pubitemid 36133308)
19. Wood SJ, Wypych J, Steavenson S, et al. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999;274: 19509-19512. (Pubitemid 129519387)
20. Conway KA, Harper JD, Lansbury PT Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000;39: 2552-2563.
21. Serpell LC, Berriman J, Jakes R, et al. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A 2000;97:4897-4902. (Pubitemid 30238654)
22. Giasson BI, Uryu K, Trojanowski JQ, Lee VM. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 1999; 274:7619-7622. (Pubitemid 129518144)
23. Lindersson E, Beedholm R, Hojrup P, et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 2004;279:12924-12934. (Pubitemid 38445867)
24. Bennett EJ, Bence NF, Jayakumar R, Kopito RR. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell 2005;17:351-365. (Pubitemid 40193307)
25. Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 2007;6:352-361. (Pubitemid 46367949)
26. Gosavi N, Lee HJ, Lee JS, et al. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem 2002; 277:48984-48992. (Pubitemid 35470870)
27. Volles MJ, Lansbury PT Jr. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol 2007;366:1510-1522.
28. Volles MJ, Lansbury PT Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002;41:4595-4602.
29. Volles MJ, Lansbury PT Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003;42:7871-7878.
30. Rochet JC, Outeiro TF, Conway KA, et al. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 2004;23:23-34.
31. Goldberg MS, Lansbury PT Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2000;2:E115-E119.
32. Tompkins MM, Hill WD. Contribution of somal Lewy bodies to neuronal death. Brain Res 1997;775:24-29.
33. Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 2002; 3:932-942.
34. Lotharius J, Brundin, P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 2002;11: 2395-2407. (Pubitemid 35174703)
35. Lotharius J, Barg S, Wiekop P, et al. Effect of mutant alphasynuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem 2002;277:38884-38894. (Pubitemid 35154753)
36. Petersen A, Puschban Z, Lotharius J, et al. Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol Dis 2002;11: 134-146. (Pubitemid 35435681)
37. Xu J, Kao SY, Lee FJ, et al. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002;8:600-606. (Pubitemid 34633438)
38. Lindgren N, Xu ZQ, Herrera-Marschitz M, et al. Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur J Neurosci 2001;13: 773-780.
39. Bunney BS, Aghajanian GK, Roth RH. Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones. Nat New Biol 1973;245:123-125.
40. Bowyer JF, Weiner N. Modulation of the Ca++-evoked release of [3H]dopamine from striatal synaptosomes by dopamine (D2) agonists and antagonists. J Pharmacol Exp Ther 1987; 241:27-33.
41. Cass WA, Zahniser NR. Inhibition of striatal dopamine release by the selective D-2 dopamine receptor agonist N-0437 is blocked by quinine. Synapse 1990;5:336-337.
42. el Mestikawy S, Glowinski J, Hamon M. Presynaptic dopamine autoreceptors control tyrosine hydroxylase activation in depolarized striatal dopaminergic terminals. J Neurochem 1986;46: 12-22.
43. Lacey MG, Mercuri NB, North RA. Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J Physiol 1987;392: 397-416.
44. Tepper JM, Nakamura S, Young SJ, Groves PM. Autoreceptor-mediated changes in dopaminergic terminal excitability: effects of striatal drug infusions. Brain Res 1984;309:317-333. (Pubitemid 14066590)
45. Parish CL, Finkelstein DI, Drago J, et al. The role of dopamine receptors in regulating the size of axonal arbors. J Neurosci 2001;21:5147-5157. (Pubitemid 32622940)
46. Parish CL, Stanic D, Drago J, et al. Effects of long-term treatment with dopamine receptor agonists and antagonists on terminal arbor size. Eur J Neurosci 2002;16:787-794. (Pubitemid 35463570)
47. Parish CL, Drago J, Stanic D, et al. Haloperidol treatment reverses behavioural and anatomical changes in cocaine-dependent mice. Neurobiol Dis 2005;19:301-311. (Pubitemid 40544748)
48. Baik JH, Picetti R, Saiardi A, et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 1995;377:424-428.
49. Kelly MA, Rubinstein M, Phillips TJ, et al. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 1998;18:3470-3479. (Pubitemid 28186038)
50. Hajos F. An improved method for the preparation of synaptosomal fractions in high purity. Brain Res 1975;93:485-489.
51. Culvenor JG, McLean CA, Cutt S, et al. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. Am J Pathol 1999;155:1173-1181. (Pubitemid 29488925)
52. Fallon JH, Moore RY. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J Comp Neurol 1978;180: 545-580.
53. Bjorklund A, Lindvall O. Dopamine-Containing Systems in the CNS. 2 vol. Amsterdam, Holland: Elsevier Science Publishers; 1984:55-122.
54. Gerfen CR, Baimbridge KG, Thibault J. The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems. J Neurosci 1987;7:3935-3944. (Pubitemid 18012406)
55. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
56. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132: 365-386.
57. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
58. Dickinson SD, Sabeti J, Larson GA, et al. Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem 1999;72:148-156. (Pubitemid 29013888)
59. Cooper AA, Gitler AD, Cashikar A, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006;313:324-328. (Pubitemid 44480951)
60. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopaminemodified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008;118:777-788. (Pubitemid 351206565)
61. Masukawa T, Sai M, Tochino Y. Methods for depleting brain glutathione. Life Sci 1989;44:417-424.
62. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134. (Pubitemid 39362633)
63. Stanic D, Parish CL, Zhu WM, et al. Changes in function and ultrastructure of striatal dopaminergic terminals that regenerate following partial lesions of the SNpc. J Neurochem 2003;86: 329-343. (Pubitemid 36842432)
64. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 1996;93:1956-1961.
65. Rabinovic AD, Lewis DA, Hastings TG. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 2000;101:67-76.
66. Norris EH, Giasson BI, Ischiropoulos H, Lee VM. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 2003;278:27230-27240. (Pubitemid 36876880)
67. Ischiropoulos H. Oxidative modifications of alpha-synuclein. Ann N Y Acad Sci 2003;991:93-100.
68. Keller JN, Hanni KB, Markesbery WR. Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mech Ageing Dev 2000;113:61-70.
69. Snyder H, Wolozin B. Pathological proteins in Parkinson's disease: focus on the proteasome. J Mol Neurosci 2004;24: 425-442. (Pubitemid 41389379)
70. Engelender S, Kaminsky Z, Guo X, et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 1999;22:110-114. (Pubitemid 29214817)
71. Giasson BI, Duda JE, Forman MS, et al. Prominent perikaryal expression of alpha-and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons. Exp Neurol 2001;172: 354-362.
72. Hsu LJ, Mallory M, Xia Y, et al. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J Neurochem 1998;71:338-344. (Pubitemid 28292567)
73. Hashimoto M, Hsu LJ, Rockenstein E, et al. alpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J Biol Chem 2002;277:11465-11472. (Pubitemid 34952915)
74. Fortin DL, Nemani VM, Voglmaier SM, et al. Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 2005;25:10913-10921. (Pubitemid 41692621)
75. Fortin DL, Troyer MD, Nakamura K, et al. Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 2004; 24:6715-6723. (Pubitemid 38993891)
76. Sidhu A, Wersinger C, Moussa CE, Vernier P. The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann N Y Acad Sci 2004;1035:250-270. (Pubitemid 40362338)
77. Sannerud R, Marie M, Nizak C, et al. Rab1 defines a novel pathway connecting the pre-Golgi intermediate compartment with the cell periphery. Mol Biol Cell 2006;17:1514-1526. (Pubitemid 44011572)
78. Smith WW, Jiang H, Pei Z, et al. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 2005;14: 3801-3811. (Pubitemid 43020082)
79. Fujita Y, Ohama E, Takatama M, et al. Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. Acta Neuropathol 2006;112:261-265. (Pubitemid 44275881)